

## Availability of documents and information for the annual shareholders' meeting of May 24, 2018

**Geneva, Switzerland, 3 May 2018** – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis and type-1 diabetes, informs its shareholders that the Annual General Meeting will be held on 24 May 2018 at 2.30pm at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.

The notice for the meeting, including the agenda of the day as well as the motions put to the vote, has been published today in the Feuille Officielle Suisse du Commerce.

The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: [www.geneuro.com](http://www.geneuro.com), under the section Investors / Documentation / Shareholders meeting.

It is also possible to consult the documents at the Company's headquarters, chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates. Each shareholder has the right to request a hard copy of those documents.

### About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis and Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 29 employees and rights to 16 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

### Contacts:

#### GeNeuro

Miguel Payró  
CFO  
+41 22 552 48 00  
[investors@geneuro.com](mailto:investors@geneuro.com)

#### NewCap (France)

Julien Perez (investors)  
+33 1 44 71 98 52  
Nicolas Merigeau (media)  
+33 1 44 71 94 98  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)

#### Halsin Partners

Mike Sinclair (media)  
+44 20 7318 2955  
[msinclair@halsin.com](mailto:msinclair@halsin.com)

#### LifeSci Advisors

Chris Maggos (investors)  
+1 646 597 6970  
+41 79 367 6254  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

**Cautionary Statement Regarding Forward-Looking Statements:** This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.